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Abstract
Background Cancer immunotherapy using bacteria dates
back over 150 years. The deeper understanding on how
the immune system interferes with the tumor microenviron-
ment has led to the re-emergence of bacteria or their related
products in immunotherapeutic concepts. In this review, we
discuss recent approaches on experimental bacteriolytic
therapy, emphasizing the specific interplay between bacteria,
immune cells and tumor cells to break the tumor-induced
tolerance.
Results Experimental research during the last decades
demonstrated beneficial but also adverse influence of bacteria
on tumor growth. There is a strong correlation between
chronic infections and tumor incidence. However, acute
bacterial infections have favourable effects on tumor
growth often contributing to complete remission. Tumor
regression is usually attributable to both direct tumor cell
killing (via apoptosis and/or necrosis, depending on the
applied bacteria) and indirect immune stimulation. This
includes (I) elimination of immunosuppressive immune cells
(i.e.tumor-associatedmacrophages,myeloid-derivedsuppres-
sor, and regulatory T cells), (II) suppression of Th2-directed
cytokine secretion (TGFα, IL10), (III) providing a pro-
inflammatory micro-milieu (tumor infiltrating neutrophils)
and(IV)supportingtheinfluxofcytotoxicTcellsintotumors.
This finally forces the development of an immunological
memoryandmayprovidelong-termprotectionagainstcancer.
Conclusion Immunotherapy using bacteria is still a double-
edged sword. Experiences from the last years have substan-
tially contributed to when bacteria and defined components
thereof might be integrated into immunotherapeutic concepts.
Attempts in transferring this approach into the clinics are on
their way.
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The interaction of mammals and especially of humans with
bacteria is among the most interesting investigative fields.
Acute bacterial infection is still one of the most feared
killers with an estimated death toll of 75,000 per year in
Germany. In the last decades it has been clearly established
that chronic infections with bacteria may additionally
contribute to this negative picture. Helicobacter pylori-
associated gastric cancer is the most prominent example.
Contrary to that, commensal microbia living on human
body’s surfaces help us in various ways by ensuring
immunity against pathogenic microorganisms. Indeed,
the number of bacteria colonizing mucosal and skin
surfaces exceeds the number of cells forming the human
body by far. The symbiotic host–commensal microflora
interactions maintain homeostasis by (i) protecting
against harmful microbiotic pathogens (viruses, bacteria,
fungi), (ii) providing a barrier against invading infectious
or immunogenic components present on the mucosa into
the circulation and (iii) exerting tolerance against harmless
antigens present on the mucosal surface [1, 2]. The growing
attention to the role of the intestinal microflora in human
health has stimulated efforts to optimize its composition
by probiotics. These orally applied live microbial cultures
(e.g. Lactobacilli, Bifidobacteria, Escherichia coli Nissle)
positively influence the microflora, inhibit pathogenic
colonization, affect the mucosal barrier and stimulate
t h ei m m u n es y s t e m[ 1].
Not so obvious, bacteria and especially bacteria-derived
p r o d u c t sa r ea l s od i r e c t l yi n v o l v e di np r o t e c t i n gh u m a n
beings from various diseases since they are widely used
for vaccination purposes.
From an evolutionary point of view, it is completely
logical that the presence of bacteria stimulates an inflamma-
tory response that finally helps to initiate memory immune
responses. The mammalian innate immune system is armed
by sensors able to recognize a plethora of biomolecules
produced exclusively by microbes. Potentially the most
important class of these molecular sensors are the so-called
toll-like receptors (TLRs). They recognize pathogen-
associated molecular pattern (PAMP) including bacterial
DNA, viral RNA, lipoteichoic acid and lipopolysaccharides.
Upon stimulation, an intracellular signaling cascade is
initiated—involving inflammatory cytokines and activation
of the innate immune system—that mediates cross-activation
of the adaptive immune system thus helping to establish
antigen-specific immune responses which have long-lasting
character.
Thisstrongpotential ofPAMP substancestounspecifically
activate the immune system has been transferred to
experimental cancer immunotherapy. Today, it is well known
that bacteria as well as bacterial components, such as
lipoteichoic acid, bacterial DNA and exotoxins/endotoxins
mediate antitumor activities not only by the earlier charac-
terized indirect activation of the immune system but
additionally by direct tumoricidal effects [3–5]. However,
there is growing experimental evidence that PAMPs may
have the opposite effect, i.e. stimulating tumor growth
under conditions of chronic inflammation [6].
In this review, we highlight recent approaches on
using bacteria as anticancer agents and discuss its potential
clinical applicability. In particular, we will focus our attention
on the controversial role of bacteria and inflammation by
having the potential of eliminating even solid tumor masses
on the one hand while driving carcinogenesis on the other.
The historical idea of using bacteria for cancer
immunotherapy
Immunotherapy is based on the idea that the patient’s
i m m u n es y s t e mc a nb es t i m u l a t e do re n h a n c e dt oa t t a c k
malignant tumors. Long before detailed knowledge on
how the immune system acts on tumors and is thus
potentially involved in inflammation-mediated tumor
shrinkage, some reports suggested that having an infection
might cause tumor regression [7]. This observation dates
back 150 years when German physicians W. Busch and
F. Fehleisen separately noticed tumor regression in can-
cer patients after accidental erysipelas infection [8, 9].
Hence, Busch was the first who intentionally inoculated
a cancer patient with erysipelas. Some years later, Fehleisen
identified Streptococcus pyogenes as the causative agent of
erysipelas [9].
At the same time, the New York surgeon William B.
Coley observed that malignant tumors, particularly sarcomas,
regressed in patients suffering from concurrent bacterial
infection whilst hospitalization [10]. He then started to
systematically treat bone and soft tissue sarcoma patients
with infectious erysipelas and in fact repetitively reported
infection-associated tumor regression. Patients usually
experienced infectious disease processes, including high
fever, chills and malaise [11]. In his first experiments,
Coley focused on treatment with live streptococci. However,
due to lethal systemic Streptococcus infection, he subse-
quently used heat-killed streptococcal organisms combined
with heat-killed Serratia marcescens (formerly known as
Bacillus prodigiosus). This bacterial vaccine became known
as “Coley’s toxin”. Coley injected more than 1000 cancer
patients with bacteria or bacterial products. He hypothesized
that an immune reaction against a “toxin” present in the
microbial material cross-reacted with and destroyed the
tumor cells [12]. Coley reported a high success rate in
treating patients with sarcomas and other malignancies,
including carcinomas (e.g. breast and renal cancer), lym-
phomas and melanomas. Thus, the inoculation of this
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immunotherapy.
During the 1920s it was insisted that the excellent
responses reported by Coley were often because the
patients had the wrong diagnoses. By 1952, the Coley’s
toxin was no longer produced, and in 1962 the Food and
Drug Administration refused to acknowledge Coley’s
toxin as a proven drug [7]. In the 1960s and 1970s,
commercial preparations of Coley’s toxin were tested
on small patient cohorts. However, results obtained by
Coley could not be reproduced, and with the emergence
of modern chemotherapy and radiotherapy, his work
gradually fell out of favor.
Recent approaches on bacterial immunotherapy
Experimental studies
Coley’s historical idea on inducing a strong inflammatory
response that leads to tumor reduction provided the basis for
developing different forms of immunotherapy. The ideal
anti-cancer therapy should selectively eradicate tumor cells,
whilst minimizing side effects to normal tissue. Today, it is
known that both direct tumoricidal effects and immune
activation force antitumor activities. During the immune
response, Toll-like receptors (TLRs) sense a diversity of
PAMPs to organize the body’s immune defense. This
includes (i) stimulation of pro-inflammatory immune cells
capable of lysing (infected) target cells in an antigen-
independent manner (neutrophils, macrophages) and (ii)
inhibition of the tumor-induced immune suppression
(tumor-associated macrophages, myeloid-derived suppressor
cells and regulatory T cells) that ideally (iii) leads to the
development of potent cellular immune responses—often
dominated by activated cytotoxic T cells—finally mediating
long-term protection against cancer.
Over the past 50 years, several strains of facultative and
obligate anaerobic bacteria were applied as oncolytic agents
due to their capacity to selectively proliferate in oxygen-
starved environments [13–17]. Based on the observation
that necrotic regions exist only within tumors and not in
normal tissues, the group of Vogelstein demonstrated that
lethal toxin-free Clostridium novyi NT spores are very
efficient in eradicating established tumors [14, 18]. They
showed that anaerobic bacteria specifically and preferentially
target solid tumors, leading to an inflammatory reaction
withinthe tumor thatisfollowed by tumor regressionin about
30%of cases [19, 20]. In a preclinical regimen, anaerobic
C. novyi NT spores were combined with conventional
drugs or radiotherapy. This strategy, referred to as combina-
tion bacteriolytic therapy (COBALT), was shown to mediate
dramatic and prolonged regression of subcutaneous tumors
following a single systemic administration [14]. Similarly,
bacteria were found to improve the efficacy of radiotherapy
in several mouse models [21]. The authors explained their
findings with the fact that efficient tumor cell killing by
radiation requires oxygen. Hypoxic cells are more resistant
to ionizing radiation than normoxic cells, and hence hypoxic
zones in poorly vascularized or necrotic tumors are a major
handicap in cancer therapy [22, 23]. By using anaerobic
bacteria, these hypoxic regions can be targeted and destroyed,
making tumors vulnerable to radiotherapy.
Of particular importance, bacteriolytic therapy was
reported to induce immunological memory. C. noyvi infection
is associated with inflammation (secretion of neutrophil-
directed cytokines) at the tumor periphery leading to
development of an effective cellular antitumoral immune
response (monocytes and lymphocytes) [14, 17, 18].
Lymphocyte transfer from cured animals into naïve
tumor-bearing mice revealed that CD8
+ cytotoxic T cells
are the main cell type involved in this process [20].
However, in a subsequent study performed by our group,
using the very same treatment protocol, similar results could
not be observed [24]. The bacterial treatment predominantly
activated the innate immune system’s arm. NK cells, but not
(tumor) antigen-specific T cells, have been activated by
bacteriolytic therapy.
Beyond that, at least in our hands, applicability of this
approach was imperfect due to troubles in standardization.
Regarding toxicity, tumor size and spore dose, we observed
that(I) small tumors (< 150 mm
3) were completely unaffected;
(II) very large tumors (> 450 mm
3) responded with substantial
necrosisfollowedbyshrinkagebutsignificantanimalmortality
and (III) an optimal treatment window exists for tumors of
approximately 250–300 mm
3 [24]. The comparably high
mortality rate in large-tumor bearing mice was most
likely attributable to the so-called “tumor lysis syndrome”
[25].SimilarexperienceshavealreadybeendescribedbyDiaz
and colleagues in a large study on evaluating pharmacology
and toxicity of C. novyi NT spores [20]. Nevertheless, a
clinical trial has been initiated in 2006, but it was terminated
due to design problems. Attempts in re-emergence of
clostridia-based therapies in the clinical setting are on their
way. In August 2011, the BioMed Valley Discoveries Inc.
started a pilot study to investigate the safety of C. novyi NT
spore administration in patients with treatment-refractory
solid tumor malignancies. The primary aim of this study
is determination of the optimal time point to initiate antibiotic
treatment in these patients. Results of this study will finally
help to estimate whether C. novyi NT-based immunotherapies
are clinically safe and feasible (Table 1).
Besides C. novyi, genetically modified strains of Salmo-
nella typhimurium have gained interest as potential antican-
cer agent, either alone or in combination with radiotherapy
and chemotherapy [26]. Zhao and coworkers designed a
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arginine and leucine, termed A1 [3]. In contrast to strictly
anaerobic bacteria, S. typhimurium growth is not confined to
necrosis and can be found throughout the tumor, including
viable regions [27]. There, bacteria invade and replicate intra-
cellular in cancer cells. But growth is not sustained in normal
tissue, indicating its potential applicability against small
tumors or maybe even micrometastases. If finally necessary,
tumor-colonizing salmonella can be readily controlled by
early post-infection systemic administration of the antibiotic
ciprofloxacin. Tumor lytic effects and accompanying specific
antitumor immune response development is preserved [28].
Thus, S. typhimurium-mediated tumor therapy might be
applied safely when combined with early antibiotic treatment.
To increasethe tumor targetingability and killing efficacy, the
A1 strain was further modified by re-isolation from a tumor
growing in a nude mouse and termed A1-R [27]. Of note, this
strain was able to eradicate metastatic lesions in orthotopic
models of breast, prostate and pancreatic cancer, both after
local as well as systemic administration [27–30].
These observations have contributed to the initiation of a
clinicalphaseItrial[31]. Twenty-fivecancer patientsreceived
bolus infusions of a lipid A-attenuated S. typhimurium
(VNP20009). This strain was safely administered to the
patients. Focal tumor colonization was observed in some
patients receiving high bacterial numbers. None of the
patients experienced objective tumor regression, including
those with colonized tumors [31]. This is a striking contrast
to the results obtained with rodent models. A conceivable
explanation is that differences with respect to tumor vascula-
ture, bacterial entry into and growth within tumors, as well as
clearance of bacteria exist between rodents and patients.
Further studies are required to finally judge if this regimen
may still be successful in the clinics.
Irrespective of the presence or absence of intratumoral
necrotic lesions, our group showed in a series of experiments
that viable as well as lysed and avitalized gram-positive
facultative anaerobic bacteria have a direct impact on tumor
growth in immunocompetent and in immunocompromised
hosts.Inaninitial work, weexploredthe antitumoral potential
of a bacteriolytic therapy based on S. pyogenes (4). This
strain was chosen as a bacterial model because (i) it exerts
direct cytolytic effects oneukaryoticcells by secreting several
cytotoxic enzymes and pore-forming toxins, (ii) it effectively
induces the secretion of proinflammatory cytokines (TNFα,
IFNγ) and chemokines (G-CSF), (iii) it mediates high influx
of inflammatory cells (e.g., neutrophils, macrophages and
NK cells) into the focus of infection and (iv) it initiates
the generation of an adaptive, cell-mediated immune
response [32, 33]( F i g .1).
S. pyogenes binds target cells via fibronectin or collagen.
Bound fibronectin acts as a bridging molecule towards host
cell integrins, which in turn initialize the uptake process that
leads to internalization (Fig. 2)[ 34]. Direct tumor cell con-
tact is thus necessary for S. pyogenes infection. This finally
leads to the induction of tumor cell apoptosis. Accordingly,
in vivo bacteriolytic therapy in tumor-bearing mice was
performed by local injection. A single application of viable
bacteria resulted in complete pancreatic carcinoma regres-
sion that was accompanied by massive immune activation
secondary to infection. As a consequence, immunological
memories, as determined by in vitro functional tests and in
vivo rechallenge experiments, developed [4]. However, as
for potential clinical application, inactivation prior to
administration seemed necessary. The streptococcal lysate
used in a subsequent study was also shown to mediate
substantial growth arrest when injected intratumorally.
Again, this antitumoral effect could be attributed to a
massive stimulation of immune response mechanisms
including a strong systemic elevation of granulocyte
numbers and an increase in tumor infiltrating cytotoxic
Tc e l l s[ 35]. Taking into consideration that the streptococcal
lysate had striking antitumoral activity even when adminis-
tered alone, it might thus be useful as immunotherapeutic
adjuvant in combination with conventional chemotherapy.
Having in mind that the innate immunity is considered to
be the sentinel of the first line defense that contributes to the
containment and elimination of microbes, we next focused
Table 1 Ongoing clinical trials on bacteriolytic cancer immunotherapy
Treatment regimen Tumor entity Specifications Phase
C. novyi NT spores Treatment-refractory solid tumor malignancies None I
Mixed bacterial vaccine (MBV) Melanoma, sarcoma, gastrointestinal stromal tumor,
head and neck cancer, transitional cell carcinoma,
prostate cancer
NY-ESO-1 expression I
Pseudomonas exotoxin A
(immunotoxin MOC31-PE)
Tumor type not specific Conjugated to anti-Ep-CAM/
epithelial glycorprotein 2
I
Urocidin (EN3348; mycobacterial
cell wall–DNA complex)
Recurrent or refractory non-muscle invasive bladder cancer BCG-pretreatment III
CpG ODN Glioma None II
Data are taken from www.clinicaltrials.gov
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phages, granulocytes, dendritic cells (DC) and NK cells. NK
cells in particular can promote tumor regression either
directly through the anti-tumor activity of type I interferons
or through cell-mediated tumor cell killing. In our study on
using avitalized staphylococci, effective tumor growth
delay was found to be accompanied by increased numbers
of tumor-infiltrating immune cells (NK cells and DC) [36].
The importance of the innate immune system on tumor
control could further be corroborated in T cell deficient mice
using human colorectal carcinoma (CRC) xenografts.
However, despite the observed significant tumor growth
control,S.aureusdidnotprovokecompletecure,independent
from the treatment regimen [36]. When comparing these
findings with previous results using live and lysed bacteria,
the adjuvant stimulus of avitalized bacteria was probably
strongenoughtobreakthetumor-inducedtolerance;however,
it is not strong enough to induce long-term immunological
responses.
To improve this regimen with respect to specific tumor
targeting, we performed experiments using conjugates of
bacteria and therapeutic monoclonal antibodies (mAb) for
experimental immunotherapy (manuscript in preparation).
This strategy is based on the idea that clinically successful
therapeutic mAb may have an additional or synergistic
impact on tumor growth. In first line treatment, therapeutic
mAbs like cetuximab and panitumumab specifically targeting
epidermal growth factor receptors (EGFR) are applied in
combination with chemotherapies [37–39]. MAb can have
effects on tumor cells by (i) disturbing receptor-mediated
Fig. 1 Scheme: bacterial immunotherapy’s mode of action. Presence
of intratumoral bacteria or bacterial components is sensitized by
innate immune cells (NK cells, macrophages, neutrophils). Tumor
d e s t r u c t i o nt a k e sp l a c et oav a r y i n gd e g r e ef o l l o w e db ys e c r e t i o no f
proinflammatory cytokines and chemokines. This attracts immature
DCs into the focus of infection. They take up bacterial material
together with tumor fragments, mature while migrating to draining
lymph nodes, where they present tumor antigens (in addition to
bacterial antigens) to T cells. Activated and expanded T cells
subsequently infiltrate the proinflammatory tumor microenvironment
where they efficiently kill tumor cells. Long-lasting antitumoral
immunity with the potential to control micrometastases forms when
part of these T cells becomes memory cells
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(iii) cell-mediated tumor cell attack. This may finally
lead to a boosted overall immune response. By using
immunocompromised mice, we performed clinically relevant
systemic injections based on the hypothesis that bacteria
coupled to tumor-specific mAb shall permit effective tumor
cell targeting in vivo thus concentrating the lytic effects of
bacteriaonthe tumor. Beyondthat, potential allergic reactions
might be minimized. Although we could not experimentally
prove tumor-targeting by bacteria–mAb conjugates, i.e.
neither bacteria nor mAbs were detectable in tumors, we
observed a substantial delay in tumor growth. This result
correlated well with immunological parameters. We found
massively increased numbers of circulating monocytes, DCs
and NK cells. This provides a basis to refine the concept on
bacteria-based combination therapies in the future.
Taken together, these studies contribute to the deeper
understanding of how bacteria or their related products act
on tumor and immune cells. Hence, bacteriolytic immuno-
therapy is still a promising alternative strategy for cancer
treatment, either alone or in combination with cytostatic
drug or antibody therapy. Future investigations will show
if these experiments stand clinical trials.
Current clinical approaches using bacteria or bacterial
preparations
Up to now, Bacillus Calmette–Guérin (BCG) is still the
most successful bacterial agent used for superficial bladder
cancer treatment [40]. BCG was introduced by Morales in
1976, based on the original development in 1921 as an
attenuated strain of Mycobacterium bovis for tuberculosis
vaccination. BCG as a live bacterium can exert local
(irritative voiding symptoms) as well as systemic (fever,
chill, malaise) effects. A functioning immune system is
required to prevent excessive reaction, and consequently
immunosuppressed patients are not considered for bacterial
therapy. Patient’s treatment is conducted on weekly
intravesical injections for 6 consecutive weeks. In some
cases adjuvant cytokines (IFN) may be added.
An inflammatory and immunological reaction, i.e. leuko-
cytosis, granulomas and urinary cytokines (IL2, IL6, IL8,
IL10, IFNγ, TNFα), was found to be positively correlated
with patients outcome. The mechanism of action is not yet
fully understood. There is, however, some degree of tumor-
specific killing by BCG, which is exclusively seen when
live bacteria are used—heat-killed bacteria have no effect.
This is due to the behavior of M. bovis as an obligate
intracellular pathogen. Hence, the mechanism of infection
can here be used for tumor therapy: BCG is taken up in a
fibronectin-dependent manner. The infected cell responds
with an inflammatory cascade (cytokine and chemokine
secretion) followed by cell lysis (in a TNF-related apoptosis
inducing ligand-specific manner), the initiation of an
unspecific neutrophils-directed reaction and the induction of
a significant Th1 response. This lastly provides long-term
adaptive immunity.
The cell wall skeleton of M. bovis is supposed to be the
major immune stimulating component. BCG–cell wall
skeleton induces IFNγ secretion and stimulates skin Lan-
gerhans cells to convert to DCs [41, 42]. Thus, it may act as
an ideal adjuvant for immunotherapy. By taking advantage
of the favorable immune effects, Mycobacterium tuberculosis
strainH37Ra,aheat-killedanddriedbacterialpreparation,has
beenwidelyappliedaspartofthecompleteFreund’sadjuvant
to attract macrophages and neutrophils to the injection
site. Complete Freund’s adjuvant is typically used for
initial injections and incomplete Freund’s adjuvant (without
H37Ra) for subsequent boosts [43, 44]. Of note, many new
candidate immunoadjuvants are tested in clinical trials in
order to treat several tumor entities. An overview of actual
recruiting trials is given in Table 2.
Fig. 2 Electron microscopy
showing S. pyogenes binding to
tumor cells. a Murine
pancreatic carcinoma cell line
(Panc02). b Human pancreatic
carcinoma cell line (AsPC1).
Bacteria adhere to tumor cells
via surface molecules. This
process, known as bacterial
adherence, is the first step of
tumor infection thus providing
the basis for subsequent tumor
cell lysis
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Besides their capacity to directly act on tumor cells, bacteria
are widely applied as delivery systems for tumor-associated
antigens in tumor immunotherapy [45]. Bacteria serve as
vectors or vehicles for (i) producing the protein of interest,
(ii) delivering cytostatic drugs or prodrug converting
enzymes and (iii) expressing cytotoxic peptides or therapeu-
tic proteins. Unlike viral gene delivery systems, bacteria
have a large capacity for genetic material insertion without
affecting the production of infectious offspring. Even
multiple different plasmids encoding for distinct antigens
and immune enhancing elements can be introduced [46, 47].
S.typhimuriumasafacultativeintracellularpathogenisoneof
the most attractive vehicles that guide the way for bacterial
oncolytic therapy. Salmonellae can be taken orally, cross the
lumen of the gut via M cells of Peyer’s Patches and are taken
up by local macrophages and DCs [48]. An innate immune
response can be generated to promote the development of
adaptive immune responses against the carried tumor-
specific antigens. Similarly, Listeria, Clostridium, Shigella
andE.colicanbeusedasexcellentvehiclesfortheproduction
and targeted delivery of therapeutic molecules into cancer
cells [49]. A comprehensive overview on how bacteria are
currently used as gene delivery vectors, the mechanisms of
action and successes at preclinical and clinical levels is
reviewed by Baban et al. 2010 [5].
Additionally, bacterial ghosts (BGs) are under experi-
mental investigation for advanced drug delivery systems of
toxic substances in tumor therapy. BGs are empty bacterial
envelopes of Gram-negative bacteria, devoid of the cyto-
plasmic content. They possess all bacterial bio-adhesive
surface properties in their original state while not posing
any infectious threat. The inner space of BGs can be loaded
with either single components or peptide combinations,
drugs or DNA which provides an opportunity to design
new types of (polyvalent) drug delivery vehicles [50].
In summary, oncolytic bacterial therapies have been
examinedincombinationwithclinicallyapplicabletreatments
such as radiotherapy and chemotherapy [45, 46]. Many of the
nascent bacterial delivery platforms described have entered
human clinical trials.
An inflammatory milieu—protumoral or antitumoral
effects?
Bacteria, either used as direct anticancer agent or as a vehicle
for cytotoxic drugs, mediate strong pro-inflammatory reac-
tions that have beneficial effects for tumor therapy. On the
contrary,thereisstrongevidencethatchronicviralorbacterial
inflammation initiates or triggers tumorigenesis [51, 52].
Epidemiological studies showed that a number of chronic
infections predispose to various tumor types. In this
regard, infection by H. pylori is associated with gastric
cancer and mucosal lymphoma, while viral infections are
related to cervical and liver cancer [53–58]. Vaccination
against such viruses has proven efficient in preventing
cancer development [59, 60].
The underlying mechanism on how bacteria and viruses
may instigate malignant transformation is in part attributable
Table 2 Ongoing clinical studies using bacterial-based immunologic adjuvants for cancer therapy with or without defined antigens
Adjuvant Tumor entity Antigen Phase
TLR3 agonist Poly-I:C (+/− Montanide and GM-CSF) Colorectal carcinoma NY-ESO-1 I/II
Peptide (URLC10-177 and TTK-567) vaccine
(+TLR9 agonist CpG ODN, +/− Montanide)
Esophageal cancer None specified I/II
Mifamurtide (L-MTP-PE, a synthetic bacterial cell
wall component) (+/− chemotherapy)
High grade osteosarcoma None specified I
TLR9 agonist PF-3512676 (+ radiation) Low grade B-cell lymphoma None specified II
TLR3 agonist Poly-I:C (+/− Montanide and GM-CSF) Melanoma NY-ESO-1 I/II
TLR7/8 agonist resiquimod + peptide vaccine (gp100) Melanoma gp100 and MAGE-3 II
TLR9 agonist CpG ODN + autologous tumor cell vaccine
(+ chemotherapy, if necessary)
Metastatic colorectal carcinoma None specified I
TLR7 agonist imiquimod (+ laser therapy) Metastatic stage III or stage IV melanoma None specified I
TLR9 agonist CpG ODN (+/− Montanide and GM-CSF) Pretreated stage II or stage III breast cancer Her2/neu/MUC1 I
TLR9 agonist EMD 1201081 + cetuximab Recurrent or metastatic head and neck squamous cell
carcinoma
None specified II
TLR7/8 agonist resiquimod + peptide vaccine Stage II, stage III, or stage IV melanoma after surgery NY-ESO-1 I
CpG ODN + (multiple) peptides (+/− Montanide) Stage III/IV melanoma patients Melan-A, Mage-10 and NY-ESO I
TLR3 agonist Poly I:C + peptide vaccine Stage IV melanoma MAGE-A3 II
OK-432 (Picibanil) + mixed vaccine Esophageal, lung, stomach, breast and ovarian cancer HER2/neu and/or NY-ESO-1 I
TLR8 agonist VTX-2337 + cetuximab Locally advanced, recurrent or metastatic squamous cell
cancer of the head and neck
None specified I
Data are collected from clinical trials listed in www.cancer.gov/clinicaltrials
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broad variety of structurally conserved molecules derived
from microbes (an overview is given in Fig. 3). On the one
hand, TLR stimulation mediates tumor cell apoptosis and
accelerates innate immune activation that is often followed
by cellular Th1-directed immune responses [61–64]. On the
other hand, TLR stimulation exerts protumoral effects by
favoring (i) tumor initiation, development and invasion,
(ii) resistance to chemotherapy and (iii) immune tolerance
[6,65–67]. Indeed, some types of tumorcells exhibitincreased
proliferation rates upon TLR stimulation [own unpublished
data]. These findings fit well with a recent study performed
by Cherfils-Vicini and colleagues, showing that TLR7 or
TLR8 stimulation of primary lung tumor cells activates
NF-kappaB, upregulates Bcl-2 expression, and increases
tumor cell survival and chemoresistance [68].
Besides microbial-induced tumorigenesis, non-pathogenic
triggers of chronic inflammation, including autoimmune
diseases (e.g. inflammatory bowel disease), enhance the
risk for malignant transformation (Fig. 4). Accordingly,
non-steroidal anti-inflammatory treatments are supposed
to decrease tumor incidence [69]. However, a very recent
publication describes controversial effect on long-term
“chemoprevention” against cancers. The authors showed
in a series of large-scale nested case–control studies that
long-term use of selective cyclooxygenase 2 inhibitors
w a sa s s o c i a t e dw i t har e d u c e dr i s ko fc o l o r e c t a lc a n c e r
(CRC), while the risk for breast cancer and haematological
malignancies (particularly lymphomas) was increased [70].
These observations underscore the bivalent role of inflamma-
tion on cancer, favoring tumor regression in the acute phase
while increasing the risk after chronic manifestation.
Two pathways describe the relationship between inflam-
mation and cancer: an intrinsic pathway, driven by genetic
alterations that cause inflammation and neoplasia (such as
oncogenes),andanextrinsicpathway,drivenbyinflammatory
leukocytes in the context of chronic infectious or persis-
tent inflammatory conditions that augment cancer risk
[71]. The latter one is attributable to microbial-induced
tumorigenesis. This facilitates a “vicious circle” characterized
by (i) local cytokine production (e.g. TNFα,w h i c hh a s
controversial roles in cancer, serving as a tumor-promoting or
tumor-destructive factor), (ii) chemokine production (CCL7,
CCL20, CCL25, CXCL1 and CCL26), (iii) secretion of
growth factors (EGF, IGF, TGFα, VEGF), (iv) suppressing
adaptive immunity and T cell function and (v) secreting
matrix-degrading enzymes (matrix-metalloproteinases, e.g.
MMP2 and 9). In solid tumors, immune cells are localized both
at the periphery and in the tumor stroma, occasionally invading
cancer cell nests. Tumor-associated macrophages (TAM) and
T lymphocytes are the most abundant immune population in
the tumor-microenvironment, although some eosinophils,
mast cells, NK cells and rare DC can be found [72].
Most of the infiltrating leukocyte subsets are effective
suppressors of antitumoral Th1-directed immune responses.
TAM (also M2 or ‘alternatively’ activated macrophages,
phenotype: IL-12
low/IL-10
high) inhibit T-cell activation via
secretion of different suppressive mediators, such as IL4,
IL13, IL10, TGFβ and indoleamine 2.3-dioxygenase (IDO)
[73, 74], as well as MHC class II down regulation. The
currently accepted concept implies the M2-polarized myeloid
cells promote tumor angiogenesis and invasion [75]. In many
but not all human tumors, a high frequency of infiltrating
TAM is associated with poor prognosis. But macrophages
Effect of the immune system on tumors 
impairment  promotion 
homeostasis 
cytokines & chemokines  
CCL7, CCL20, CCL25, 
CXCL1, CCL26  
Growth factors & cytokines 
(EGF, IGF, VEGF, TGF , IL10, IL17)  
Th2-directed immune response 
Regulatory T cells;  MDSC 
Immune suppression   Proinflammatory cells (neutrophils, 
macrophages, NK cells) 
TLR-agonists 
(bacterial DNA, viral 
RNA, LTA, LPS) 
cytokines & chemokines     
(IL6, IL8, G-CSF, TNF , IFN ) 
Th1-directed immune response 
Cytotoxic T cells 
Bacterial 
immunotherapy 
tumor-induced 
tolerance 
Fig. 3 Scheme: balance of physiological immunity in the tumor context. LTA (lipoteichoic acid), LPS (lipopolysaccharide)
564 Langenbecks Arch Surg (2012) 397:557–568may act as a double-edged sword in cancer, since these cells
can be re-educated to exert antitumor activity [76, 77]. It was
demonstrated that IL12 injection induced a pro-immunogenic
potential of TAM while reducing tumor-supportive activities
[78].
In the context of an inflammatory response, myeloid cells
are the primary recruited effectors. In tumors, these cells are
represented by myeloid-derived suppressor cells (MDSCs).
Murine MDSCs are referred to as CD11b
+Gr1
+, which are
the predominant population of tumor-associated myeloid
cells. Similar to TAMs, increased numbers appear in the
blood during tumor growth in mice (Fig. 5), with some
being recruited to the tumor site to promote angiogenesis
[73, 79]. Of note, myeloid cells infiltrating tumors may
induce tumor cell resistance to CTLs by modifying the
peptide–MHC complexes on tumor cells via reactive
oxygen species [79]. These modifications reduce the
capacity of the tumor cells’ M H Ct ob i n da n t i g e n i c
peptides and subsequent recognition by CTLs. This provides
a novel concept regarding tumor escape associated with
inflammation and might have consequences for therapeutic
approaches focusing on pharmacological reactive oxygen
species inhibition [79].
Finally,regulatoryTcells(phenotype:CD4
+CD25
+FOXP3
+
CD127
low) which have been identified long time ago
contribute to the general tumor-specific T cell tolerance.
Tregs are activated in an antigen-specific manner but are
believed to suppress T cells in an antigen-non-specific
Duration of 
inflammation  Tumor risk  
acute 
chronic 
>10 
years 
1 week 
1 month 
1 year 
5 years 
established tumor 
Intraepithelial 
neoplasia 
Regenerative 
hyperplasia 
Inflammation-induced 
carcinogenesis 
Normal 
epithelia 
before 
Fig. 4 Scheme: relationship between inflammation and tumor devel-
opment. Ulcerative colitis associated tumors develop over decades in a
multistep process characterized by defined morphological alterations.
Regenerative hyperplasia characterizes the body’s attempts to restore
gut function after an acute inflammatory episode. Intraepithelial neo-
plasia develops when this regenerative stimulus becomes chronic.
Finally genetic alterations triggered by inflammation-induced DNA
damage force tumor development
Langenbecks Arch Surg (2012) 397:557–568 565manner [71]. While Treg accumulation at high density in
tumors is generally related to a poor outcome, in patients
suffering from CRC, high Treg infiltration is associated
with a favorable clinical prognosis [80]. To explain this
irony, the dense microbiological flora present in the gut
requires a T-cell-mediated inflammatory anti-microbial
response that, among others, involves Th17 cells [81].
This Th17-cell-dependent proinflammatory and tumor-
enhancing response can be attenuated by Tregs, thus
reconstituting the balance between pro-inflammatory and
anti-inflammatory effects in the gut that may contribute to the
favorable role in CRC prognosis. The link between a high
density of FOXP3-positive Tregs in CRC may lead to a
paradigm shift and thus help to decide when immunotherapy
based onthe integration of bacteria or microbial structures
is feasible and safe.
Summary and outlook
Bacterial-induced inflammation is a double-edged sword. In
an acute phase, bacteria massively activate the immune
system initiating an unspecific, often neutrophil-directed
r e a c t i o nt h a ti sf o l l o w e db yaT h 1o rc y t o t o x i cTc e l l
directed cellular response. This lastly provides long-term
protective immunity. However, when starting to be chronic,
inflammation triggers tumorigenesis by suppressing
adaptive immunity and T cell function. An immune
status characterized by tolerance towards self but altered
cells arises that finally drives tumor progression. Expe-
riences from the last years helped to get deeper insight
into the mechanisms, and hence attempts in dealing with
t h ef i n el i n eb e t w e e np r o t u m o r al and antitumoral effects
to finally re-establish homeostasis are on their way. However,
questions remain for which tumor type bacterial-based
therapy will be applicable, since differences exist between
tumor entities with a tendency towards better responses
intumors that arise ina sterile microenvironment compared
tothose coming from a non-sterile, bacterial-experienced
background (i.e. the gut).
Bacteria and their components, i.e. mainly defined TLR-
ligands(PAMPs)canbesafelyappliedinhumanswithlimited
adverse side effects and are thus established in the clinic as
immunostimulatory adjuvants. Combination therapies are al-
so being investigated for potential future applications.
Finally, several findings argue in favor of bacteria for
immunotherapy compared to viruses. These include (i) safety
of application; even when using live bacteria, secure control
canbeguaranteedduetotheirantibioticsensitivity;(ii)several
bacterial ligands (PAMPs) are known to directly act on im-
mune and tumor cells; (iii) fewer problems in terms of prac-
ticability of usage, production and prize; and (iv) fewer size
restrictions when generating transgenics expressing tumor
target genes, therapeutic proteins or prodrug converting
enzymes. Bacterial ghosts may even be used to deliver-
ing anticancer agents or cytotoxic peptides, directly.
These findings provide a ready basis for further priming
the concept of bacterial cancer immunotherapy for the clin-
ical setting.
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